The Company is a biopharmaceutical company that has established a diverse drug development platform to actualize therapeutics indicated for the treatment of cancer and neuropathic pain. The company’s lead cancer product is a depressor amine therapeutic that is used in conjunction with cytokine therapy to maintain remission of cancer in patients with Acute Myeloid Leukemia (AML). Although individuals treated for AML typically achieve complete remission of the cancer, where it is no longer detectable, approximately 75-80% of these patients will experience a relapse that leads to a poor prognosis, and the company’s therapeutic has been shown in clinical studies to significantly increase the leukemia-free survival of AML patients in remission. Additionally, the company has developed two separate cancer therapeutics which function by promoting programmed cell death, both of which are currently in clinical trials indicated for the treatment of solid tumors. For the treatment of chronic pain the company has developed a topical analgesic cream that is indicated for the treatment of peripheral neuropathies where nerves in the periphery of the body produce abnormal pain sensation in patients. The company’s analgesic cream consists of two FDA approved compounds and has been shown in clinical studies to be successful for the abatement of pain experienced from diabetic neuropathy and post-herpetic neuropathy, and is currently in clinical trials indicated for the treatment of chemotherapy-induced neuropathy. Importantly, the company’s topical analgesic has a superior safety profile in comparison to currently used systemic pain medications, as it precludes the onset of serious side effects including dizziness and somnolence, and also greatly reduces the potential for drug abuse.